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Novel coronavirus disease (COVID-19) was initially diagnosed with flu (influenza)-like symptoms and respiratory distress in December 2019 in Wuhan, China ([@bib1]). However, further studies showed a few neurological symptoms in some patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) such as headache, languidness, unstable walking, and malaise ([@bib2]), cerebral hemorrhage ([@bib3]), and cerebral infarction ([@bib4]). According to the study on 241 definitive patients with COVID-19, more than one third of patients had neurological manifestations; its severity varied depending on the progression of the disease, e.g., patients with more severe infection had acute cerebrovascular diseases, impaired consciousness, and skeletal muscle injury ([@bib3]). Another study showed acute necrotizing encephalopathy (ANE) in the brain magnetic resonance imaging (MRI) of the patient with COVID-19. Images from brain MRI demonstrated hemorrhagic rim, enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular region ([@bib5]).

The exact reason for involvement of central nervous system (CNS) in COVID-19 is still unclear. It seems that the lung epithelial cells are infected with COVID-19 because of angiotensin-converting enzyme 2 (ACE2) receptor ([@bib6]). The virus binds to the receptor through the protein S, which helps the virus genome to enter the human epithelial cell ([@bib6]). Cerebral hemorrhage due to increased blood pressure could be a consequence of the ACE2 receptor expression, affected by COVID-19 ([@bib7]). Indeed the serum samples of patients with COVID-19 show coagulopathy and prolonged prothrombin time ([@bib8]). Increasing D-dimer due to COVID-19 could subsequently lead to intracranial clots and cerebral hemorrhage ([@bib9]).

ANE is a fatal complication that rarely results from an indirect viral invasion such as influenza ([@bib10]). According to the pathology of ANE, an overreaction of the immune cells to a viral infection leads to a cytokine storm ([@bib11]), which could break the blood-brain barrier ([@bib11]). Current evidences suggest cytokine storm in COVID-19 ([@bib12],[@bib13]), which could be the cause of ANE in affected patients ([@bib5]).

It should be mentioned that SARS-CoV was previously detected in the cerebrospinal fluid (CSF) of SARS patients with epilepsy ([@bib14]). Therefore as of structural and genetic similarities between SARS and SARS-CoV2 ([@bib15]), the potential risk of entering SARS-CoV-2 to the CSF of patients with COVID-19 should be considered.

Finally, it should be emphasized that almost all recent studies on COVID-19 indicated that the SARS-CoV2 infection is not limited to the respiratory system. So, as of the importance of neurological damage, any neurological sign and symptom of patients with COVID-19 should be closely monitored.
